Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has signed consent~2. Age \> 18 years~3. Subjects with a CF-LVAD or are scheduled to receive a CF-LVAD implant~Exclusion Criteria:~1. Psychiatric disorder or disease, irreversible cognitive dysfunction or psychosocial issues that might impair compliance with the study.~2. Patients already taking fish oil.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primary Prevention Intervention (Type: EXPERIMENTAL): In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
- Primary Prevention Non-Intervention (Type: PLACEBO_COMPARATOR): In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
- Secondary Prevention Intervention (Type: EXPERIMENTAL): In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
- Secondary Prevention Non-Intervention (Type: PLACEBO_COMPARATOR): In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).